MS Wire

Biomedical engineers have developed a self-assembling nanomaterial that can help limit damage caused by inflammatory diseases by activating key cells in the immune system. In mouse models of psoriasis, the team showed that their nanofiber-based drug co…

A new study reveals how chronic inflammation promotes muscle fibrosis, which could inform the development of new therapies for patients suffering from Duchenne muscular dystrophy (DMD), a fatal muscle disease.

A team of researchers has determined that the type of fats a mother consumes while breastfeeding can have long-term implications on her infant’s gut health. Their study suggests that the type of fat consumed during breastfeeding could differentially im…

Despite a similar clinical presentation, people with severe asthma have strikingly distinct immune profiles, research shows. These findings can be used to develop new therapeutics and enhance precision medicine approaches to treating these patients.

Immune checkpoint inhibitors boost a patient’s immune response against cancer cells, but they can cause potentially life-threatening side effects in some individuals. New research may help clinicians determine which patients are most at risk.

Immune checkpoint inhibitors are life-saving therapies against advanced cancer, but they can cause side effects, most commonly involving the skin. New research provides insights on the extent of these side effects, when they tend to arise, and which pa…

Researchers have advanced a tumor-targeting and cell penetrating antibody that can deliver payloads to stimulate an immune response to help treat melanoma.

Researchers have identified a failure in the brain’s immune system that can lead to the amplification of cell division and spread of glioblastoma cancer cells.

A personalized cancer vaccine raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinic…

Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study.